Endocrine Abstracts

Amiodarone induced thyrotoxicosis (AIT) may develop in patients with either underlying thyroid disorders (type 1) or normal gland (type 2). The latter is considered a drug-induced destructive thyroditis, usually responding to glucocorticoids. Further treatments after restoring euthyroidism are often not necessary. The former is a true form of iodine-induced hyperthyroidism the management of which includes thionamides, potassium perchlorate and thyrodectomy. The prevalence of t...

Context: Therapy with somatostatin analogues (SSAs) may have deleterious effects on glucose metabolism in patients with acromegaly, often leading to development of diabetes mellitus (DM).Aim of the study: To evaluate whether DM, which developed during therapy with SSAs, may revert after drug withdrawal and cure of acromegaly with pituitary adenomectomy.Design: Retrospective cohort study, in a tertiary referral center.<p class="...

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

Autosomal dominant hypocalcemia type 1 (ADH1) is a genetic disorder characterized by low serum calcium and low or inappropriately normal levels of PTH. It is caused by a heterozygous activating mutation of the calcium-sensing receptor (CASR) gene, resulting in decreased sensitivity of the receptor to low serum calcium. The aim of our study was to describe a series of patients with ADH1 followed at our outpatient clinic from 2011 to 2023. A total of 7 patients (4 femal...

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant disorder, characterized by the predisposition to the development of multiple endocrine tumors mainly affecting parathyroids, gastroenteropancreatic neuroendocrine tissues (GEP-NET) and pituitary (PT). Mutations of the MEN1 gene are responsible for the disease and may be inherited from one of the parents or more rarely can occur de novo. In children and adolescence there is a paucity of cl...

Objectives: The primary objective was to study the prevalence and the risk factors of vertebral fractures (VFs) in acromegaly patients either at diagnosis of acromegaly or during the follow-up. The role of routine chest radiography for detecting VFs in acromegaly was also evaluated.Design and methods: A retrospective cohort study was performed on 60 consecutive acromegaly patients, in a tertiary referral center. The presence of VFs was firstly evaluated ...

Objective: Destructive thyroiditis is the most common endocrine immune related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE. Nevertheless in patients with enlarged thyroid volume and a poor performance status, thyrotoxicosis may be particularly severe and harmful. Aim of the study is to evaluate if steroid treatment might be useful in improving thyrotoxicosis in subj...

Introduction: Polychlorinated biphenyls (PCBs) are environmental pollutants that modulate endocrine functions, induce tumorigenesis, and regulate apoptosis in several tissues; however, their effects on the apoptosis of pituitary cells is unknown.The aim of this study was to evaluate the PCBs influence on the apoptosis of normal pituitary cells and elucidate the molecular mechanisms involved.Methods: Primary cell cultures from mouse...

BackgroundThyrotoxicosis is a common immune-related adverse event in patients treated with PD1 or PD-L1 blockade. A detailed endocrinological assessment, including thyroid ultrasound and scintigraphy is missing, as are data on response to treatment and follow-up. Aim of the study was to better characterize the thyrotoxicosis secondary to immune checkpoint inhibitors, gaining insights into pathogenesis and informing management.Metho...

The clinical diagnosis of MEN1 is established when a proband manifests at least two of the manifestations of the triad (Primary Hyperparathyroidism (PHPT), Pituitary adenoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)). Typically, it is a familial disease (F-MEN1), while in about 10% of cases the disease is sporadic. In sporadic forms (S-MEN1), up to 70% of patients may exhibit a negative genetic analysis (MEN1-negative). These patients seem to have distinc...